[go: up one dir, main page]

WO2018008973A1 - Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique - Google Patents

Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique Download PDF

Info

Publication number
WO2018008973A1
WO2018008973A1 PCT/KR2017/007168 KR2017007168W WO2018008973A1 WO 2018008973 A1 WO2018008973 A1 WO 2018008973A1 KR 2017007168 W KR2017007168 W KR 2017007168W WO 2018008973 A1 WO2018008973 A1 WO 2018008973A1
Authority
WO
WIPO (PCT)
Prior art keywords
peripheral neuropathy
extract
preventing
pharmaceutical composition
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/007168
Other languages
English (en)
Korean (ko)
Inventor
방옥선
김노수
김진희
이진무
이유진
김영아
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018008973A1 publication Critical patent/WO2018008973A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to a composition for the prevention, improvement or treatment of peripheral neuropathy (peripheral neuropathy) containing a Forsythiae Fructus extract as an active ingredient.
  • Peripheral neuropathy is caused by a disease that directly damages or affects nerve tissue. Depending on the type of nerve tissue affected, sensory neuropathy and motor neuropathy neuropathy) and autonomic neuropathy. In sensory neuropathy, sensation of touch and tremor, sensation of temperature change, tingling or burning pain, and allodynia in the skin are experienced. Motor neuropathy is accompanied by loss of balance and muscle weakness. In autonomic neuropathy, the ability to control the bladder is weakened depending on the organs affected by the nerve, resulting in incontinence or abnormal blood pressure and heart rate. Induced (RA Hughes, 2002, BMJ, v324, pp466-469; JM Torpy et al., 2010, JAMA, v303, p1556).
  • CIPN chemotherapy-induced peripheral neuropathy
  • CIPN-related symptoms include numbness, tingling, burning, cold and pain in the fingers and toes, and loss of feel and strength (T. Armstrong et al., 2005) , Oncol Nurs Forum, v32, pp305-311; C. Visovsky et al., 2008, Clin J Oncol Nurs, v12, pp243-247).
  • Anticancer agents known to cause CIPN include platinum, taxane, vinca alkaloids, bortezomib or thalidomide, and the incidence of CIPN depends on the type and dose of anticancer agent used. And 20-75%, depending on the duration of administration (G. Cavaletti et al., 2011, Curr Treat Options Neurol, v13, pp180-190).
  • the mechanism of neurotoxicity caused by anticancer drugs is not exactly known. However, it is assumed that the mechanisms by which anticancer drugs act on general cancer cells and the mechanisms on peripheral nervous system cells are similar to each other. It is known that anticancer agents administered to patients accumulate not only in cancer tissues but also in the peripheral nervous system, and the accumulation of such anticancer agents eventually causes neurotoxicity and cause CIPN.
  • Forsythia Fructus refers to the dried fruit of the ash of Forsythia viridissima Lindley or Forsythia suspensa Vahl, which is used as a medicinal herb in Japan, but in China It is known to use only dried fruit of Dangari forsythia without using.
  • Yeon-kyo is the name that fruit is formed in a room similar to lotus, and it rises long among various grasses. Or, if a seed is split, a piece and a piece are similar to feathers, so it is known that it is called a bridge using a kite that means 'to touch' and a bridge that means 'feather'. This drug has a peculiar smell, its bitter taste, and a little cold.
  • the drug has the effect of lowering and detoxifying the fever, eliminating wind and fever, and causing boils and cuts to swell, swell, or loosen the swelling. Therefore, the fever can be lowered early in the fever to reduce the fever and mental confusion, or can be used to boil, lymphadenitis, and sore throat. In ideology, it is a medicine that can be used by Soyangin. As a pharmacological action, antibacterial action, anti-inflammatory action, blood pressure drop, hemostatic action, liver treatment action, antipyretic effect, clay, diuretic action have been reported.
  • the main chemicals include forsythol, sterol compounds, saponins, and oleanolic acids.
  • Appearance is oval or long oval granules, with pointed ends and fruit stems at the base.
  • the outer surface is light brown or dark brown with scattered light gray small ridges and two vertical grooves.
  • the well-done splits along the longitudinal groove and the end is twisted.
  • the inside of the split rind is yellowish brown with a septum in the middle. Seeds have elongated oval wings.
  • Korean Patent Publication No. 2016-0062303 discloses a composition for the prophylaxis or treatment of an immune disease containing a duct extract, and Korean Patent Publication No. 2009-0047501 contributes to the treatment of neuropathy induced by chemotherapy. It is disclosed with respect to the method and pharmaceutical preparations, Korean Patent Publication No. 2014-0123444 discloses a pharmaceutical composition and health functional food for the prevention or treatment of cancer comprising a natural product extract as an active ingredient, There is no disclosure regarding a composition for preventing, improving or treating peripheral neuropathy containing the extract as an active ingredient.
  • the present invention is derived from the above requirements, the present invention provides a composition for preventing, ameliorating or treating peripheral neuropathy containing a duct extract as an active ingredient.
  • the present invention reduces pain response by administering the duct extract to an animal model in which peripheral neuropathy was induced by the administration of oxaliplatin, and inhibited neuronal toxicity and neurite growth by oxaliplatin as the duct extract was treated in nerve cells.
  • the present invention was completed by confirming that the mitigatory extract did not affect the cytotoxicity of lung cancer and colorectal cancer cell lines by oxaliplatin.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of peripheral neuropathy (peripheral neuropathy) containing a duct extract as an active ingredient.
  • the present invention provides an anticancer adjuvant containing the duct extract as an active ingredient.
  • the present invention provides a health functional food composition for the prevention or improvement of peripheral neuropathy (peripheral neuropathy) containing a duct extract as an active ingredient.
  • peripheral neuropathy peripheral neuropathy
  • the present invention relates to a composition for the prevention, improvement or treatment of peripheral neuropathy (peripheral neuropathy), in particular, chemotherapy-induced peripheral neuropathy caused by an anticancer agent, containing as a active ingredient extract, specifically Yeongyo extract of the present invention does not affect the intrinsic cytotoxic effects of anticancer agents in human cancer cell lines, and at the same time mitigates neuronal cytotoxicity and neurite growth inhibition by anticancer agents, and increased pain in animal models of anticancer drug induced peripheral neuropathy. The effect is to effectively reduce the sensitivity to stimulation.
  • peripheral neuropathy peripheral neuropathy
  • chemotherapy-induced peripheral neuropathy caused by an anticancer agent containing as a active ingredient extract, specifically Yeongyo extract of the present invention does not affect the intrinsic cytotoxic effects of anticancer agents in human cancer cell lines, and at the same time mitigates neuronal cytotoxicity and neurite growth inhibition by anticancer agents, and increased pain in animal models of anticancer drug induced peripheral neuropathy.
  • the effect is to effectively reduce the sensitivity to stimulation.
  • 1 is a ratio of cells forming neurites when treated with increasing concentrations of GF extracts of the present invention (WEFF) sequentially in PC-12 cells induced with nerve growth factor (NGF) (A ) And a graph showing the sum of the lengths of the grown neurites (B) and the effect of the neurites growing under a microscope (C).
  • WEFF GF extracts of the present invention
  • Figure 2 shows that after the induction of neuronal differentiation of PC-12 cells using nerve growth factors, the treatment of oxaliplatin induced the toxicity of neurons and the duct extract of the present invention protects neurons. ** indicates that the toxicity of neurons was statistically significant by treatment with oxaliplatin as compared to PC-12 cells ((-) Oxal + (-) WEFF) not treated with oxaliplatin, p ⁇ 0.01 , ## means that when treated with ductile water extract of the present invention compared to the control treated with oxaliplatin and vehicle (PBS), there is a statistically significant neuroprotective effect of reducing the toxicity of neurons, p ⁇ 0.01.
  • Figure 3 is injected once a week, 10 times / total (20 mg / kg) intraperitoneal injection of 10 mg / kg oxaliplatin to induce peripheral neuropathic pain in the mouse model (C57BL / 6), pontoon water extract (WEFF) is a graph showing the weight change measured by daily oral administration.
  • WEFF pontoon water extract
  • ** and *** indicate a statistically significant increase in pain response in animal models administered oxaliplatin compared to normal, ** is p ⁇ 0.01, and *** is p ⁇ 0.001.
  • the test was performed with von Frey filament with 0.4g (A) and 0.16g (B) bending force.
  • ##, ### indicates that the oxaliplatin administered group compared to the oxaliplatin + vehicle (0.5% CMC solution) administration group, and the response to pain in the group administered the ductal water extract of the present invention statistically significantly reduced ## is p ⁇ 0.01 and ### means p ⁇ 0.001.
  • Figure 5 is a result confirming the relative viability of the lung cancer cell lines (A549, A) and colon cancer cell lines (HCT116, B) treated with the ductile water extract of the present invention in combination with oxaliplatin.
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of peripheral neuropathy (peripheral neuropathy) containing a duct extract as an active ingredient.
  • the duct bridge extract is preferably extracted with water, a lower alcohol of C 1 ⁇ C 4 or a mixture thereof as a solvent, the lower alcohol is preferably methanol or ethanol.
  • the duct bridge extract is preferably prepared by a manufacturing method including the following steps, but is not limited thereto.
  • step 3 drying the filtered extract of step 2) under reduced pressure.
  • the bridge of step 1) can be used without limitation, such as grown or commercially available.
  • the extraction method of the duct bridge extract of step 1) conventional methods in the art such as filtration, hot water extraction, dipping extraction, reflux cooling extraction, and ultrasonic extraction may be used.
  • the extraction solvent is preferably extracted by adding 2 to 40 times the volume based on the weight of the dried duct bridge. Extraction temperature is preferably 20 ⁇ 100 °C but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 1 to 4 hours, most preferably 2 hours is not limited thereto.
  • the extraction is preferably repeated 2-3 times, but is not limited thereto.
  • the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the peripheral neuropathy is preferably a chemotherapy-induced peripheral neuropathy induced by an anticancer agent
  • the anticancer agent is a platinum-based, taxane-based, vinca alkaloids, bortezomib ( bortezomib) or thalidomide, including, but not limited to, all anticancer agents that are clinically, pharmacologically and biomedically available.
  • the platinum-based anticancer agent is preferably at least one selected from cisplatin, carboplatin, and oxaliplatin, and the taxane-based anticancer agent is preferably at least one selected from paclitaxel and docetaxel. It is not limited to this.
  • compositions of the present invention may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions or syrups, and include various excipients such as wetting agents, sweeteners, fragrances or preservatives, in addition to the commonly used simple diluents such as water and liquid paraffin. Can be.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations or suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • injectable ester such as ethyl oleate, and the like
  • suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol, gelatin, and the like may be used.
  • the pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to select an external skin or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection method for parenteral administration. I never do that.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • the pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to the medical treatment, and the effective dose level refers to the type, severity, drug activity, and drug of the patient. Sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
  • the dosage of the composition of the present invention varies depending on the patient's weight, age, sex, health status, diet, time of administration, administration method, excretion rate and severity of the disease, the daily dosage is the amount of duct extract It is 0.01-1000 mg / kg, Preferably it is 30-500 mg / kg, More preferably, it is 50-300 mg / kg, It can be administered 1-6 times a day. However, the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • the pharmaceutical composition of the present invention is preferably used in combination with an anticancer agent, but may be used alone or in combination with methods using surgery, radiation therapy, hormonal therapy, and biological response modifiers.
  • the present invention relates to an anticancer adjuvant containing duct extract as an active ingredient.
  • the anticancer adjuvant is preferably administered in combination with an anticancer agent including platinum, taxane, vinca alkaloids, bortezomib or thalidomide, and is caused by an anticancer agent.
  • an anticancer agent including platinum, taxane, vinca alkaloids, bortezomib or thalidomide
  • the present invention also relates to a nutraceutical composition for the prevention or improvement of peripheral neuropathy (peripheral neuropathy) containing a duct extract as an active ingredient.
  • peripheral neuropathy peripheral neuropathy
  • the duct bridge extract is preferably extracted with water, a lower alcohol of C 1 ⁇ C 4 or a mixture thereof as a solvent, the lower alcohol is preferably methanol or ethanol.
  • the duct bridge extract is preferably prepared by a manufacturing method including the following steps, but is not limited thereto.
  • step 3 drying the filtered extract of step 2) under reduced pressure.
  • the bridge of step 1) can be used without limitation, such as grown or commercially available.
  • the extraction method of the duct bridge extract of step 1) conventional methods in the art such as filtration, hot water extraction, dipping extraction, reflux cooling extraction, and ultrasonic extraction may be used.
  • the extraction solvent is preferably extracted by adding 2 to 40 times the volume based on the weight of the dried duct bridge. Extraction temperature is preferably 20 ⁇ 100 °C but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 1 to 4 hours, most preferably 2 hours is not limited thereto.
  • the extraction is preferably repeated 2-3 times, but is not limited thereto.
  • the decompression concentration in step 3) preferably uses a vacuum decompression concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the peripheral neuropathy is preferably a chemotherapy-induced peripheral neuropathy induced by an anticancer agent
  • the anticancer agent is a platinum-based, taxane-based, vinca alkaloids, bortezomib ( bortezomib) or thalidomide, including, but not limited to, all anticancer agents that are clinically, pharmacologically and biomedically available.
  • the platinum-based anticancer agent is preferably at least one selected from cisplatin, carboplatin and oxaliplatin, and the taxane-based anticancer agent is preferably at least one selected from paclitaxel and docetaxel. It is not limited to this.
  • the health functional food composition may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like, but is not limited thereto and may be manufactured and processed in any form according to the law.
  • the composition containing the duct extract of the present invention as an active ingredient may be added as it is to food or used together with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient can be suitably determined according to the purpose of use (prevention or improvement).
  • the amount of the extract in the health food can be added to 0.1 to 90 parts by weight of the total food weight.
  • the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • the health functional food composition of the present invention When used as a beverage, there is no particular limitation on other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and various flavors or natural carbohydrates are added as in the general beverage. It may contain as a component.
  • the natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents tautin, stevia extract (e.g., Rebaudioside A, glycyrginine, etc.)
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the duct extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • the duct extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The ratio of such additives is not so important, but is generally selected in the range of 0.1 to 20 parts by weight per 100 parts by weight of duct extract.
  • the duct bridge extract of the present invention 100 g of the dried duct bridge purchased from Gwangmyeongdang Pharmaceutical Co., Ltd. (Ulsan, South Korea) was ground to prepare a sample in powder form. 100 g of ground dry sample and 2 l of water Put into a round flask and mix. A water bath connected to a reflux extractor with a cooling tube was heated and extracted twice, once every two hours. The extracted extract was filtered under reduced pressure using a paper filter paper (Whatman No. 2) and a vacuum pump (GAST). The filtered liquid extract was concentrated under reduced pressure using a rotary evaporator (YEYELA). The concentrated extract was lyophilized and then homogenized with a mortar and pestle to obtain soft water extract (WEFF). The resulting soft water extract was placed in a sealed plastic container and stored at 4 ° C. cold storage until the experiment.
  • GEEYELA rotary evaporator
  • PC-12 cells to be used in the Examples for confirming the effect of the duct extract of the present invention is a rat-derived Chromocytocytoma (Pheochromocytoma), when the neuronal growth factor (NGF) is treated to finally differentiate into neurons It is a cell line that is useful as a cell model of neurological research because of its characteristics.
  • PC-12 cells were treated with 5% (v / v) non-heat inactivated fetal bovine serum (FBS), 10% (v / v) heat inactivated horse serum (HS), Coating with collagen type I in an incubator maintained at 37 ° C., 5% (v / v) CO 2 using DMEM growth medium containing 100 units / ml penicillin and 100 ⁇ g / ml streptomycin Cultured in a 100 mm cell culture dish.
  • FBS non-heat inactivated fetal bovine serum
  • HS heat inactivated horse serum
  • Human lung cancer cells (A549) and human colon cancer cells (HCT116) were treated at 37 ° C. using RPMI1640 growth medium containing 10% (v / v) heat inactivated FBS, 100 units / ml penicillin, 100 ⁇ g / ml streptomycin.
  • the cells were cultured in 100 mm cell culture dishes in an incubator maintained at 5% (v / v) CO 2 and used for later in vitro experiments.
  • CIPN chemotherapy-induced peripheral neuropathy
  • results obtained in the examples of the present invention were expressed as mean ⁇ standard deviation (mean ⁇ SD) or mean ⁇ standard error (mean ⁇ SE), and the statistical mean comparison between groups was T-test and ANOVA / Tukey post-hoc. The test was conducted. p values were expressed as * ⁇ 0.05, ** ⁇ 0.01, *** ⁇ 0.001.
  • Example 1-1 Determination of Neuronal Growth Inhibitory Effect of Yeon-kyo Water Extract
  • the neurite outgrowth inhibitory effect of the water extract of Fructus of the present invention was confirmed. Specifically, the cultured PC-12 cells were uniformly inoculated in a 24 well plate coated with collagen type IV at a concentration of 1 ⁇ 10 4 cells / well, and then cultured in DMEM growth medium to adhere to the bottom surface. After 24 hours, the cells were replaced with DMEM medium containing 100 ng / ml neuronal growth factor (NGF) without serum to induce the production of neurites, and treated with 200 nM oxaliplatin to induce neurotoxicity.
  • NGF neuronal growth factor
  • the prepared soft water extract (WEFF) was treated at concentrations of 12.5, 25, 50, and 100 ⁇ g / ml, respectively, and after 3 days, observed with an optical microscope to analyze the ratio of neurites-produced cells and the length of neurites. It was.
  • oxaliplatin oxaliplatin
  • the cultured PC-12 cells were uniformly inoculated into a 96 well plate coated with collagen type IV at a concentration of 2 ⁇ 10 3 cells / well and then cultured in DMEM growth medium to adhere to the bottom surface. After 24 hours, differentiation into neurons was induced by replacing with DMEM medium containing 100 ng / ml of neuronal growth factor (NGF) without serum to induce neurites. Four days later, 200 nM of oxaliplatin was treated to induce cytotoxicity to neurons.
  • the prepared soft water extract (WEFF) was treated at concentrations of 25, 50, and 100 ⁇ g / ml, respectively, and after 2 days, viability of each well was measured using Ez-cytox.
  • the experimental animal group administered oxaliplatin decreased body weight compared to the normal group, and after induction of CIPN for 2 weeks, the group administered oral extract (WEFF) orally was 0.5 as vehicle. Compared with the group administered the% CMC solution, no side effects such as weight loss were seen, but rather recovered faster than the vehicle administration group (FIG. 3).
  • CMC carboxymethyl cellulose
  • WEFF soft water extract
  • each cell was divided into 5 x 10 3 cells per well in a 96 well culture dish. After 24 hours, oxaliplatin (0-100 ⁇ g / ml) and soft water extract (100 ⁇ g / ml) diluted sequentially were treated simultaneously. The negative control group was treated with oxaliplatin and used a cell group treated with PBS as a vehicle instead of the soft water extract. After 72 hours of treatment, cell viability was measured using an Ez-Cytox cell viability measurement kit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition, comprenant comme principe actif un extrait de Forsythiae Fructus, et visant à prévenir, soulager ou traiter la neuropathie périphérique, en particulier la neuropathie périphérique induite par chimiothérapie (NPIC). De façon plus détaillée, un extrait de Forsythiae Fructus de la présente invention atténue la neurotoxicité et la suppression de la croissance des neurites induites par des agents anticancéreux, et réduit efficacement la sensibilité aux stimuli douloureux augmentés dans des modèles animaux de neuropathie périphérique induite par la chimiothérapie, sans affecter la cytotoxicité intrinsèque des agents anticancéreux dans des lignées de cellules cancéreuses humaines.
PCT/KR2017/007168 2016-07-06 2017-07-05 Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique Ceased WO2018008973A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160085589A KR101732483B1 (ko) 2016-07-06 2016-07-06 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
KR10-2016-0085589 2016-07-06

Publications (1)

Publication Number Publication Date
WO2018008973A1 true WO2018008973A1 (fr) 2018-01-11

Family

ID=59051145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/007168 Ceased WO2018008973A1 (fr) 2016-07-06 2017-07-05 Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique

Country Status (2)

Country Link
KR (1) KR101732483B1 (fr)
WO (1) WO2018008973A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022262241A1 (fr) * 2021-06-16 2022-12-22 爱非克(深圳)生物科技有限公司 Extrait de feuilles de forsythia suspensa et son utilisation pour augmenter l'abondance d'akk dans des tractus intestinaux

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101732483B1 (ko) * 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070045988A (ko) * 2005-10-28 2007-05-02 김선여 마과 식물의 추출물 및 이를 포함하는 말초신경병증의 예방또는 치료용 조성물
US20090143464A1 (en) * 1998-07-30 2009-06-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Method for preventing and/or treating peripheral Neuropathies induced by the administration of an anticancer agent
WO2012105476A1 (fr) * 2011-01-31 2012-08-09 日本臓器製薬株式会社 Médicament prophylactique ou thérapeutique pour neuropathie périphérique provoquée par un agent anticancéreux
WO2012149267A1 (fr) * 2011-04-27 2012-11-01 Yale University Pharmacothérapie pour empêcher des effets indésirables induits par une chimiothérapie et compositions pharmaceutiques, diagnostics, techniques de dépistage et trousses associés
KR101732483B1 (ko) * 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009028605A1 (ja) 2007-08-31 2010-12-02 国立大学法人九州大学 抗がん剤による末梢神経障害の予防又は軽減剤
EP3295946B1 (fr) 2015-05-12 2020-08-19 Korea Institute of Oriental Medicine Composition, contenant un extrait de lithospermi radix en tant que principe actif, pour prévenir, soulager, ou traiter la neuropathie périphérique
KR101695207B1 (ko) 2015-07-31 2017-01-11 한국 한의학 연구원 상륙 추출물을 유효성분으로 함유하는 항암제 유발 말초신경병증 예방 또는 치료용 약학적 조성물
KR101689513B1 (ko) 2015-10-06 2016-12-27 한국 한의학 연구원 백부근 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143464A1 (en) * 1998-07-30 2009-06-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Method for preventing and/or treating peripheral Neuropathies induced by the administration of an anticancer agent
KR20070045988A (ko) * 2005-10-28 2007-05-02 김선여 마과 식물의 추출물 및 이를 포함하는 말초신경병증의 예방또는 치료용 조성물
WO2012105476A1 (fr) * 2011-01-31 2012-08-09 日本臓器製薬株式会社 Médicament prophylactique ou thérapeutique pour neuropathie périphérique provoquée par un agent anticancéreux
WO2012149267A1 (fr) * 2011-04-27 2012-11-01 Yale University Pharmacothérapie pour empêcher des effets indésirables induits par une chimiothérapie et compositions pharmaceutiques, diagnostics, techniques de dépistage et trousses associés
KR101732483B1 (ko) * 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022262241A1 (fr) * 2021-06-16 2022-12-22 爱非克(深圳)生物科技有限公司 Extrait de feuilles de forsythia suspensa et son utilisation pour augmenter l'abondance d'akk dans des tractus intestinaux

Also Published As

Publication number Publication date
KR101732483B1 (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
US20100316741A1 (en) Composition comprising the extract of crude drug complex for stimulating bone growth
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
KR100869443B1 (ko) 뽕잎, 계피 및 포도씨 추출물을 포함하는 혈당강하용조성물
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
RU2540511C2 (ru) Фармацевтическая композиция и пищевая функциональная оздоровительная композиция для предупреждения, лечения или облегчения желудочно-кишечных дискинетических заболеваний
KR102752074B1 (ko) 차즈기 추출물을 유효성분으로 하는 근 위축증 또는 근 감소증 예방 또는 치료용 조성물
KR20200102348A (ko) 지골피 추출물을 유효성분으로 함유하는 근 위축 예방 또는 치료용 조성물
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
KR102251534B1 (ko) 작약 및 감초 혼합 추출물을 포함하는 구강건조증 예방 또는 치료용 약학적 조성물
WO2018080157A1 (fr) Composition pour la prévention, le soulagement ou le traitement d'un déficit cognitif, contenant un extrait de ficus erecta en tant que principe actif
WO2014133286A1 (fr) Composition contenant des extraits d'artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l'inhibition ou le traitement de maladies se rapportant à l'obésité
KR20140080289A (ko) 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법
WO2018030650A1 (fr) Composition anti-obésité contenant un extrait de feuilles de chrysanthème en tant que principe actif
WO2021246703A1 (fr) Composition anti-obésité
WO2021002547A1 (fr) Composition destinée à prévenir, atténuer ou traiter un syndrome d'andropause, comprenant un extrait de scutellaria barbata en tant que principe actif
WO2021085741A1 (fr) Composition d'amélioration ou de traitement de la maladie d'alzheimer comprenant comme principe actif du tetragonia tetragonioides
KR101735294B1 (ko) 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법
WO2020122385A1 (fr) Composition comprenant un extrait d'élécampane pour soulager un symptôme de syndrome prémenstruel
US20100074975A1 (en) Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea L. Var. Edulis extract
KR102561751B1 (ko) Blb301(블랙라즈베리 및 속단 복합추출물)을 포함하는 근육 질환의 예방, 치료 또는 개선용 조성물
KR102671544B1 (ko) 복합 한약재 추출물을 유효성분으로 포함하는 스트레스 완화 및 면역증진용 조성물
WO2025234773A1 (fr) Composition pour améliorer la mémoire et prévenir, soulager ou traiter une déficience cognitive, contenant un extrait de galium odoratum en tant que principe actif
KR20250031426A (ko) 골담초근 추출물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물
KR20250031435A (ko) 한련초 추출물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물
KR20250031428A (ko) 홍화자 추출물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17824529

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17824529

Country of ref document: EP

Kind code of ref document: A1